51. Scleroderma Clinical trials / Disease details


Clinical trials : 523 Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013468-37-GB
(EUCTR)
29/09/201017/03/2010A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon. - Asasantin retard therapy in the management of Raynaud's phenomenonA short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon. - Asasantin retard therapy in the management of Raynaud's phenomenon Primary Raynaud's Phenomenon and Systemic Sclerosis
MedDRA version: 12.1;Level: LLT;Classification code 10042953;Term: Systemic Sclerosis
MedDRA version: 12.0;Classification code 10037917;Term: Raynaud's phenomenon
Trade Name: Asasantin Retard ®
Product Name: ASASANTIN Retard
INN or Proposed INN: aspirin
INN or Proposed INN: dipyridamole
Royal National Hospital for Rheumatic DiseaseNULLNot Recruiting Female: yes
Male: yes
70 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom